Skip to main
AKTS

AKTS Stock Forecast & Price Target

AKTS Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aktis Oncology is forecasted to have a bright future as a result of their promising pipeline products, AKY-1189 and AKY-2519. With a strong collaboration agreement generating revenue and a discounted cash flow-based valuation methodology projecting a market value of $1.93B and a 12-month price target of $35 per share, there is strong potential for growth and development. Risks to the price target include negative clinical results, delays in advancing pipeline candidates, and competitive risks; however, with sufficient cash to fund operations until 2029, the company has the resources to overcome these challenges and achieve success.

Bears say

Aktis Oncology is a clinical-stage oncology company focused on developing targeted radiopharmaceuticals for solid tumors. Despite a partnership generating revenue, Aktis is a highly speculative investment due to its lack of current products on the market and ongoing losses. A major factor in the negative outlook is the uncertainty surrounding the success of Aktis' pipeline programs, as well as the potential for future dilution of shares to fund their development.

AKTS has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aktis Oncology Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aktis Oncology Inc (AKTS) Forecast

Analysts have given AKTS a Buy based on their latest research and market trends.

According to 4 analysts, AKTS has a Buy consensus rating as of Jun 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aktis Oncology Inc (AKTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.